Evan David Seigerman
Stock Analyst at BMO Capital
(3.49)
# 933
Out of 5,124 analysts
54
Total ratings
52.08%
Success rate
5.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan David Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Upgrades: Outperform | $82 → $130 | $105.26 | +23.50% | 5 | Dec 18, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $725 → $850 | $771.87 | +10.12% | 9 | Dec 4, 2025 | |
| AMGN Amgen | Maintains: Outperform | $335 → $372 | $327.31 | +13.65% | 5 | Dec 3, 2025 | |
| NVO Novo Nordisk | Maintains: Market Perform | $50 → $46 | $50.88 | -9.59% | 8 | Nov 25, 2025 | |
| REPL Replimune Group | Upgrades: Market Perform | $2 → $11 | $9.72 | +13.17% | 5 | Nov 3, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $215 → $240 | $228.49 | +5.04% | 8 | Sep 12, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $22 → $26 | $20.53 | +26.64% | 2 | Jun 12, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $24 → $28 | $26.71 | +4.83% | 2 | May 19, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $20 → $10 | $11.86 | -15.68% | 1 | May 5, 2025 | |
| IRON Disc Medicine | Maintains: Outperform | $70 → $112 | $79.41 | +41.04% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $83 → $100 | $69.55 | +43.78% | 2 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 → $36 | $24.90 | +44.58% | 4 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $3 | $5.65 | -46.90% | 1 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $369 → $396 | $1,074.68 | -63.15% | 1 | Sep 6, 2022 |
Merck & Co.
Dec 18, 2025
Upgrades: Outperform
Price Target: $82 → $130
Current: $105.26
Upside: +23.50%
Regeneron Pharmaceuticals
Dec 4, 2025
Maintains: Outperform
Price Target: $725 → $850
Current: $771.87
Upside: +10.12%
Amgen
Dec 3, 2025
Maintains: Outperform
Price Target: $335 → $372
Current: $327.31
Upside: +13.65%
Novo Nordisk
Nov 25, 2025
Maintains: Market Perform
Price Target: $50 → $46
Current: $50.88
Upside: -9.59%
Replimune Group
Nov 3, 2025
Upgrades: Market Perform
Price Target: $2 → $11
Current: $9.72
Upside: +13.17%
AbbVie
Sep 12, 2025
Maintains: Outperform
Price Target: $215 → $240
Current: $228.49
Upside: +5.04%
Neurogene
Jun 12, 2025
Maintains: Outperform
Price Target: $22 → $26
Current: $20.53
Upside: +26.64%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $24 → $28
Current: $26.71
Upside: +4.83%
Arvinas
May 5, 2025
Maintains: Outperform
Price Target: $20 → $10
Current: $11.86
Upside: -15.68%
Disc Medicine
Nov 5, 2024
Maintains: Outperform
Price Target: $70 → $112
Current: $79.41
Upside: +41.04%
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $69.55
Upside: +43.78%
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $24.90
Upside: +44.58%
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $5.65
Upside: -46.90%
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $1,074.68
Upside: -63.15%